v3.26.1
EARNINGS PER COMMON SHARE
6 Months Ended
Jun. 30, 2026
EARNINGS PER COMMON SHARE [Abstract]  
EARNINGS PER COMMON SHARE

Note 4 — Earnings per Common Share:

Basic earnings per common share is computed by dividing earnings, after the deduction of dividends and undistributed earnings allocated to participating securities, by the weighted average number of common shares outstanding during the period.

The computation of diluted earnings per share assumes the issuance of common stock for all potentially dilutive stock options and restricted stock units not classified as participating securities. Participating securities are included in the computation of earnings per share pursuant to the two-class method.

Weighted average shares of unvested restricted common stock considered to be participating securities totaled 24,965 and 26,510 for the three and six months ended June 30, 2026, respectively, and 20,683 and 19,204 for the three and six months ended June 30, 2025, respectively. As of June 30, 2026, there were 494,491 shares of restricted stock units and 26,713 stock options outstanding and considered to be potentially dilutive securities.

Reconciliations of the numerator and denominator of the basic and diluted earnings per share computations are as follows:

Three Months Ended June 30,

Six Months Ended June 30,

(Dollars in thousands)

2026

2025

2026

2025

Numerator:

Net income allocated to:

Common stockholders

$

294,818

$

61,616

$

580,829

$

111,163

Participating securities

107

30

239

48

$

294,925

$

61,646

$

581,068

$

111,211

Denominator:

Weighted-average common shares outstanding, basic

49,487,271

49,323,071

49,474,189

49,315,304

Dilutive effect of stock options

20,128

77,564

34,911

78,522

Dilutive effect of performance-based restricted stock units

263,787

38,933

218,653

35,768

Dilutive effect of restricted stock units

86,379

36,913

94,691

73,097

Weighted-average common shares outstanding, diluted

49,857,565

49,476,481

49,822,444

49,502,691

There were no antidilutive equity awards outstanding during the three and six months ended June 30, 2026 and 2025, respectively.